查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
中东·非洲的AI支援医疗影像市场
市场调查报告书
商品编码
1803895

中东·非洲的AI支援医疗影像市场

MEA (Middle East & Africa) AI-assisted Medical Imaging Market
出版日期: | 出版商: Marketstrat, Inc. | 英文 24 Pages | 订单完成后即时交付

价格

中东和非洲正从试点阶段迈向规模化发展，其市场规模将从美国的2,500万美元（2023年）成长至2032年的5亿美元（复合年增长率为24%）。在撒哈拉以南非洲地区，低频宽DR/超音波AI将透过营运支出模式和远距放射学模式推广。本报告提供了不同国家、不同医疗模式和不同买家在AI辅助医学影像市场的布局和胜利之道。

五大关键统计

  • 1. 规模与发展速度：2,500万美元至5亿美元（2023-2032年，复合年增长率为24%）。
  • 2. 海湾合作委员会（GCC）占有率： 超过60%的区域支出（沙乌地阿拉伯、阿联酋、卡达、科威特、阿曼、巴林）。
  • 3.到2032年，医疗模式组合变化：CT 占 36%-23%，MRI 占 32%-39%，X光/DR 占 16%-22%。
  • 4. 临床引擎：肿瘤科、心臟科和中风科将占绝对成长的最大占有率。
  • 5. 收入来源：在非洲，硬体占有率将下降，软体/服务占有率将上升，云端/按次付费将成长最快。

买方利益

  • 国家/地区策略（海湾合作委员会、北非、撒哈拉以南非洲）、行动、合作伙伴和定价原型。
  • CT/MR 捆绑套餐与 DR/美国营运成本方案的比较，并采用阶梯式费率和平均售价区间。
  • 采购和託管清单（阿拉伯语使用者介面、资料驻留、GCC 安全/品质管理系统、非洲边缘/离线）。
  • 证明预算一致性（从门到针、TAT、节省的剂量/时间）并获得企业批准。
  • 框架驱动的 GTM（成长和成熟度、生态系统协作、解决方案采用和成长）。

方法论与品质保证：

双视角模型：自上而下连结到全球总量，自下而上连结连结率驱动因素（出货量、改造和平均销售价格）。采用中东/非洲特定权重（SFDA/MOHAP/SAHPRA 讯号、捐赠者/PPP 模式），并总结了 QA 循环，涵盖总计 <0.5%、监管差距检查、证据新鲜度和 ASP 健康状况。

特点

  • 涵盖范围：海湾合作委员会 (GCC)、北非和撒哈拉以南非洲地区；按治疗方式、临床区域、最终用途、收入来源、最终用途和国家细分。
  • 关键数据： 2,500 万美元 → 5 亿美元，复合年增长率 24%
  • 用例： OEM 捆绑包、纯通路策略、Telerad 规模化、捐赠资助项目

目录

章节1-摘要整理

章节2-调查手法

章节3-市场概要与分析-中东·非洲

  • 中东·非洲市场概述
  • 逻辑簇和重要性
  • 主要的成长催化剂
  • 结构性障碍与缓解措施
  • 供应商类别的实用的推荐事项
  • 定序蓝图
  • 执行的要点

章节4-市场预测-中东·非洲

  • 中东·非洲市场，各临床领域(2023年～2032年)
  • 中东·非洲市场，各种模式(2023年～2032年)
  • 中东·非洲市场，不同收益来源(2023年～2032年)
  • 中东·非洲市场，各临床用途(2023年～2032年)
  • 中东·非洲市场，各最终用途组织(2023年～2032年)
  • 中东·非洲市场，各AI技术(2023年～2032年)

章节5-MARKINTEL解决方案的招聘与成长矩阵-中东·非洲

  • 解释和运用蓝图

章节6-MARKINTEL生态系统合作矩阵-中东·非洲

  • 伙伴关係剧本
  • 运用蓝图主要的实行指标

章节7-GTM概要(中东·非洲)

  • GTM 准备情况雷达 - 中东和非洲
  • 国家集群热图 - 中东和非洲
  • GTM 时间表 - 试点到规模化 (2024-2029) - 中东和非洲
  • 邻近机会雷达 - 中东和非洲
  • GTM 成熟度亮点 - 中东和非洲
  • 监理速度 - 中东和非洲
  • 安装率趋势 - 中东和非洲
Product Code: MINTP-M01124

Report Headline:

MEA is shifting from pilots to selective scale-rising from ~US$25M (2023) to ~US$500M by 2032 (~24% CAGR). GCC anchors >60% of spend with enterprise AI suites, while Sub Saharan Africa scales low bandwidth DR/ultrasound AI via opex models and teleradiology. This Pulse translates evidence into where to play and how to win-per country, modality, and buyer.

Five Key Stats:

  • 1. Size & pace: ~US$25M -> ~US$500M (2023-2032, ~24% CAGR).
  • 2. GCC share: >60% of regional spend (KSA, UAE, Qatar, Kuwait, Oman, Bahrain).
  • 3. Modality mix shift: CT 36%->23%, MRI 32%->39%, X ray/DR 16%->22% by 2032.
  • 4. Clinical engines: Oncology, Cardiology, and Stroke account for most absolute growth.
  • 5. Revenue streams: Hardware share declines; Software/Service rise; Cloud/Pay per Use grows fastest in Africa.

Buyer Benefits:

  • Country specific playbooks (GCC, North Africa, Sub Saharan) with actions, partners, and pricing archetypes.
  • Attach rate ladders & ASP bands to package CT/MR bundles vs. DR/US opex offers.
  • Procurement & hosting checklists (Arabic UI, data residency, security/QMS for GCC; edge/offline in Africa).
  • Evidence to budget alignment (door to needle, TAT, dose/time saved) to unlock enterprise approvals.
  • Framework driven GTM (Growth & Maturity, Ecosystem Collaboration, Solution Adoption & Growth).

Methodology & QA:

Dual lens model: top down tie out to global totals + bottom up attach rate engine (shipments, retrofit, ASPs). MEA specific weighting (SFDA/MOHAP/SAHPRA signals; donor/PPP patterns). QA loop: sum to total less than or equal to 0.5%, regulatory diff checks, evidence freshness, ASP sanity.

Features at a glance:

  • Coverage: GCC, North Africa, Sub Saharan Africa; splits by modality, clinical area, application, revenue stream, end use, country
  • Key numbers: ~US$25M -> ~US$500M; ~24% CAGR
  • Use cases: OEM bundling, pure play channel strategy, telerad scale up, donor funded programs

TABLE OF CONTENTS

SECTION 1 - EXECUTIVE SUMMARY

  • The 25-second read
  • Size & Pace (where dollars concentrate)
  • Modality Mix (MEA, 2023 -> 2032)
  • Clinical pathways (MEA, 2023 -> 2032)
  • Revenue Stream Dynamics
  • Country/Cluster Snapshots
  • 12-month actions (MEA "Pulse Quick-wins")

SECTION 2 - RESEARCH METHODOLOGY

  • Scope & Segmentation
  • Dual-Lens Architecture
  • MEA-Specific Inputs & Weighting
  • Assumptions & calibration choices (MEA)
  • Quality assurance (standard Pulse QA)
  • Limitations & Mitigations

SECTION 3 - MARKET OVERVEW & ANALYSIS - MEA

  • MEA Market Snapshot
  • Logical Clusters & Why They Matter
  • Key Growth Catalysts
  • Structural Barriers & Mitigation
  • Actionable Recommendations by Vendor Type
  • Sequencing Roadmap
  • Executive Takeaways

SECTION 4 - MARKET ESTIMATES & FORECASTS - MEA

  • MEA Market by Clinical Area (2023-2032)
    • Growth Drivers & Restraints
  • MEA Market by Modality (2023-2032)
    • Modality Share Shifts
  • MEA Market by Revenue Stream (2023-2032)
    • Revenue Stream Shifts & Strategic Implications
  • MEA Market by Clinical Application (2023-2032)
    • Clinical Application Shifts & Takeaways
  • MEA Market by End-Use Organization (2023-2032)
    • End-User Adoption Patterns
  • MEA Market by AI Technology (2023-2032)
    • Technology Shifts and Takeaways

SECTION 5 - MARKINTEL SOLUTION ADOPTION & GROWTH MATRIX - MEA

  • Interpretation & Operating Roadmap
    • Execution Checklist

SECTION 6 - MARKINTEL ECOSTSYSTEM COLLABORATION MATRIX - MEA

  • Partnership Playbook
  • Operating Roadmap & Key Execution Metrics

SECTION 7 - GTM AT-A-GLANCE (MEA)

  • GTM Readiness Radar - MEA
  • Country Cluster Heatmap - MEA
  • GTM Timeline - Pilot to Scale (2024-2029) - MEA
  • Adjacency-Opportunity Radar - MEA
  • GTM Maturity Highlights - MEA
  • Regulatory Velocity - MEA
  • Attach Rate Trends - MEA

List of Figures

  • Figure 1: Markintel Solution Adoption & Growth Matrix - MEA
  • Figure 2: Markintel Ecosystem Collaboration Matrix - MEA
  • Figure 3: GTM Readiness Radar - MEA
  • Figure 4: Country Cluster Heatmap - MEA
  • Figure 5: GTM Timeline - Pilot to Scale (2024-2029) - MEA
  • Figure 6: Adjacency-Opportunity Radar - MEA
  • Figure 7: Regulatory Velocity - MEA
  • Figure 8: Attach Rate Trends - MEA

List of Tables

  • Table 1: Middle East and African (MEA) Market by Clinical Area (2023-2032, USD Million)
  • Table 2: Middle East and African (MEA) Market by Modality (2023-2032, USD Million)
  • Table 3: Middle East and African (MEA) Market by Revenue Stream (2023-2032, USD Million)
  • Table 4: Middle East and African (MEA) Market by Clinical Application (2023-2032, USD Million)
  • Table 5: Middle East and African (MEA) Market by End-Use Organization (2023-2032, USD Million)
  • Table 6: Middle East (MEA) Market AI Technology (2023-2032, USD Million)